Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: soliris + data + american  Related to the article below (Last Update: 8/4/2008)

I need help: a website strategy and design issue
ZDNet - Jul 29, 2008
Geeklog?s software seems perfect for that, is free, installs easily on Solaris, and scales well enough to support noted geeklog users like groklaw. ...
Wall Street rises on oil slide and financials
Reuters - Jul 29, 2008
Stocks were also helped by data showing the rate of monthly price declines in the US housing market is slowing and a separate report showing the mood of ...
GLOBAL MARKETS-US stocks rise on bank rally, oil's new fall
guardian.co.uk, UK - Jul 22, 2008
You also see the dollar up," said Tim Ghriskey, chief investment officer of Solaris Asset Management in Bedford Hills, New York. ...
Sun Microprofit
Forbes, NY - Aug 1, 2008
Clouds over the American economy are casting a shadow on Sun Microsystems. The maker of heavy-duty computer hardware and software took a big hit on Friday ...JAVA
Zacks Analyst Blog Highlights: Corel Corporation, Alexion ...
FOXBusiness - Jul 9, 2008
The launch of Alexion Pharmaceuticals' (Nasdaq: ALXN) genetic disorder drug Soliris in Australia and Japan in 2009, coupled with the drug's approval in one ...CREL - ALXN - APEI
The Ghost in Your Machine: IPv6 Gateway to Hackers
Wired News - Jul 18, 2008
In 2002, Lance Spitzer of the Honeynet Project revealed that one of the Honeynet's Solaris honeypots in the US was compromised by an intruder who entered ...
Analyst Comments: PLATO, Akzo Nobel, American Public, El Paso, Alexion
istockAnalyst.com, OR - Jul 8, 2008
Long-term treatment with Soliris was also found to be associated with significant improvement and stabilization of kidney function. Data presented at the ...TUTR - OTC:AKZOY - APEI
Sr. Design Engineer, Core Network
Seattle Post Intelligencer - Jul 11, 2008
T-Mobile USA is a national provider of wireless voice, messaging, and data services capable of reaching over 268 million Americans where they live, work, ...
EADS' A330-Based Tanker for the Royal Australian Air Force to ...
SYS-CON Media, NJ - Jul 15, 2008
This innovative product combination will allow enterprise customers to run Solaris/SPARC applications on the latest Windows-based serv By Dare Obasanjo What ...
Source: Google News

FDA Approvals: Keppra and Soliris CME -
L Disclaimer - medscape.com
... OneSource) also is available (http://www.soliris.net ... should verify all information
and data before treating ... to 200 Prescribed credits by the American Academy of ...

[PDF] Antibody Technologies Rise to New Challenges -
R Das, KJ Morrow Jr - Bioprocessing, 2006 - isc-newsletter.com
... Soliris is indicated for the treat- ment of ... of acceptance by Euro- pean and American
regulatory bodies ... While preliminary data are encouraging, it certainly will ...

-
AA Baud, O Poulet - US Patent 7,071,836, 2006 - Google Patents
... keted by the applicant under the names Centralis or Soliris, this change ... In American
patent US Pat ... source, the remote control unit gathers the data relating to ...
-

Experts say preoperative chemotherapy often best for breast cancer. -
K Traynor - American Journal of Health-System Pharmacy, 2007 - pt.wkhealth.com
... Alexion said patients and their pre- scribing physicians must enroll in the Soliris
Safety Registry ... New data from B-18 that were present- ed at the NCI meeting ...
-

-
AA Baud, O Poulet - US Patent 7,079,045, 2006 - Google Patents
... In American patent US Pat. No. ... data relating to the appliances (lamps, domestic
appliances, ... keted by the applicant under the names Centralis or Soliris, ...
-

IMPROVEMENT FOR A REMOTE CONTROL THAT CAN SWITCH BETWEEN OPERATING MODES -
AA BAUD, O POULET - EP Patent 1,415,290, 2004 - freepatentsonline.com
... by the applicant under the names Centralis or Soliris, this change of ... [0015] In American
patent US ... source, the remote control unit gathers the data relating to ...
-

C5 Blockade with Conventional Immunosuppression Induces Long-Term Graft Survival in Presensitized …
RP Rother, J Arp, J Jiang, W Ge, SJ Faas, W Liu, … - American Journal of Transplantation, 2008 - Blackwell Synergy
... American Journal of Transplantation. ... antihuman C5 monoclonal antibody (eculizumab,
SOLIRIS ? ) for the ... hemoglobinuria (PNH) (92?94), the data presented here ...
-

AUTHOR AND EDITOR INFORMATION
EC Besa - emedicine.com
... of death were different with more thrombotic deaths seen in American patients. ... Drug
Name, Eculizumab (Soliris). ... Interactions, Limited data exist; none reported. ...
-

The Mesoamerican Venus Symbol In Venezuelan Rock Art -
P Domingo S?nchez - kacike.org
... We know examples of that serpent figure found in the North American and also in
Venezuelan rock art. ... Authors? Data Base. ... P. Soliris Linares (detail). 1979. 15?. ...

5G1. 1, h5G1. 1, Long-Acting Anti-C5 Monoclonal Antibody 5G1-1, Long-Acting Anti-C5 Monoclonal …
ARD Profile - ingentaconnect.com
... antibody 5G1-1, 5G1.1, h5G1.1, Abstract monoclonal antibody 5G1.1, Soliris?] is
a ... 2007 Adis Data Information BV ... tive component of the American College of Rheu ...

Source: Google Scholar
 
 

Soliris (eculizumab) Data To Be Presented At American Society Of Hematology

Article Date: 14 Dec 2006 - 4:00 PST
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has announced that abstracts relating to Soliris™ (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts were presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris™ (eculizumab) PNH clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website. Access to the on-line abstracts may require registration, for which there is no charge.

The following abstracts were presented in oral sessions:

* "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria"

Dr. Peter Hillmen et al.

* "Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III TRIUMPH Study Results"

Dr. Jorg Schubert et al.

The following abstracts were presented in poster sessions:

Article continues below and (thank you)
 
* "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study"

Poster # 99-I

Dr. Neal S. Young et al.

* "Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization"

Poster #100-I

Dr. Anita Hill et al.

###

About PNH and Soliris(TM)

PNH, a rare and life-threatening form of hemolytic anemia, is an acquired genetic blood disorder characterized by destruction of red blood cells by the body's complement system (a component of the immune system). Patients with PNH lack naturally-occurring complement inhibitors which normally prevent red blood cell destruction. Soliris™ (eculizumab), a long-acting C5 terminal complement inhibitor, is an investigational humanized monoclonal antibody drug that is designed to selectively block terminal complement activation and thereby restore complement inhibition in the blood of patients with PNH. Soliris™ (eculizumab) has been granted Orphan Drug Status in the PNH indication from both the FDA and European regulatory agencies. There currently is no approved therapy specifically available for treatment of PNH.

About Alexion

Alexion Pharmaceuticals is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Alexion's lead product candidate, Soliris™ (eculizumab), is currently undergoing evaluation in several clinical development programs, including for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Under the Special Protocol Assessment (SPA) process, the FDA has agreed to the design of protocols for the two phase III trials of Soliris™ (eculizumab) in PNH patients. In January, 2006, Alexion announced that the first of those two PNH trials, the TRIUMPH study, achieved its co- primary endpoints with statistical significance. In June 2006, Alexion announced that interim results from the second of those two PNH trials, the SHEPHERD study, showed that eculizumab appeared to be safe and well tolerated and that all primary and secondary efficacy endpoints were achieved with statistical significance. In September, 2006, Alexion applied for marketing authorization with both the United States Food and Drug Administration and the European Medicines Evaluation Agency for the use of Soliris™ (eculizumab) in PNH patients. Results from the TRIUMPH and SHEPHERD trials served as the primary basis for the marketing applications filed in the United States and Europe. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com/.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris™ (eculizumab), clinical trial results, the progress of Soliris™ (eculizumab) towards commercial sales, timing for acceptance of, and potential regulatory decisions with respect to, marketing applications for Soliris™ (eculizumab). Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including delays in completing ongoing clinical trials, delays in completing analysis of clinical trial results, requests by the FDA or other regulatory authorities for additional information or data either prior to their acceptance of our submissions for filing or after their review of our submissions, timing and evaluation by regulatory agencies of the results of these and other clinical trials, the results of pre-clinical or clinical studies (including termination or delay in clinical programs), the need for additional research and testing, decision of the FDA or other regulatory authorities not to approve (or to materially limit) marketing of Soliris™ (eculizumab), delays in arranging satisfactory manufacturing capability, delays in developing commercial infrastructure, inability to acquire funding on timely and satisfactory terms, delays in developing or adverse changes in commercial relationships, the possibility that results of earlier clinical trials are not predictive of safety and efficacy of Soliris™ (eculizumab), the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms, the risk that third party payors will not reimburse for the use of Soliris™ (eculizumab) at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2006 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward- looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Contact: Tony Russo
Euro RSCG Life NRP
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page